EMERYVILLE, Calif.,
Nov. 2, 2020 /PRNewswire/
-- Dynavax Technologies Corporation (NASDAQ: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, today announced that Ryan
Spencer, Chief Executive Officer, will present at the Stifel
2020 Virtual Healthcare Conference on Monday, November 16, at 3:30 p. m. E.T.
The live audio webcast may be accessed through the "Events &
Presentations" page on the "Investors" section of the Company's
website at www.dynavax.com. A replay of the webcast will be
available for 30 days following the live event.
About Dynavax
Dynavax is a commercial stage
biopharmaceutical company developing and commercializing novel
vaccines. The Company's first commercial product, HEPLISAV-B®
[Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the
U.S. for prevention of infection caused by all known subtypes of
hepatitis B virus in adults age 18 years and older. Dynavax is also
advancing CpG 1018 as a premier vaccine adjuvant through global
research collaborations and partnerships. Current
collaborations are focused on adjuvanted vaccines for COVID-19,
pertussis and universal influenza. For more information, visit
www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndt, Senior Manager,
Investor Relations
narndt@dynavax.com
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-stifel-2020-virtual-healthcare-conference-301165128.html
SOURCE Dynavax Technologies